Botulinum Neurotoxin Serotype F: Identification of Substrate Recognition Requirements and Development of Inhibitors with Low Nanomolar Affinity
- 12 February 2005
- journal article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 44 (10) , 4067-4073
- https://doi.org/10.1021/bi0477642
Abstract
Botulinum neurotoxins (BoNTs A-G) are zinc metalloendoproteases that exhibit extraordinary specificities for proteins involved in neurotransmitter release. In view of the extreme toxicities of these molecules, their applications in human medicine, and potential for misuse, it is of considerable importance to elucidate the mechanisms underlying substrate recognition and to develop inhibitors, with the ultimate goal of obtaining anti-botulinum drugs. We synthesized peptides based on vesicle-associated membrane protein (VAMP) to investigate the substrate requirements of BoNT F, which cleaves VAMP between residues Q58 and K59. The minimum substrate was a peptide containing VAMP residues 32-65, which includes only one of the two VAMP structural motifs thought to be required for botulinum substrate recognition. BoNT F exhibited a strict requirement for residues D57 (P(2)), K59 (P(1)'), and L60 (P(2)'), but peptides containing substitutions for R56 (P(3)), Q58 (P(1)), and S61 (P(3)') were cleaved. Therefore, the P(2), P(1)', and P(2)' residues of VAMP are of paramount importance for BoNT F substrate recognition near the scissile bond. K(i) values of uncleavable analogues were similar to K(m) values of the substrate, suggesting that substrate discrimination occurs at the cleavage step, not at the initial binding step. We then synthesized inhibitors of BoNT F that incorporated d-cysteine in place of glutamine 58, exhibited K(i) values of 1-2 nM, and required binding groups on the N-terminal but not the C-terminal side of the zinc ligand. The latter characteristic distinguishes BoNT F from other zinc metalloendoproteases, including BoNTs A and B.Keywords
This publication has 23 references indexed in Scilit:
- Dual Toxin-Producing Strain of Clostridium botulinum Type Bf Isolated from a California Patient with Infant BotulismJournal of Clinical Microbiology, 2004
- A novel strategy for designing specific gelatinase A inhibitors: potential use to control tumor progressionCritical Reviews in Oncology/Hematology, 2004
- Translocation of botulinum neurotoxin light chain protease through the heavy chain channelNature Structural & Molecular Biology, 2002
- Botulism Due to Clostridium baratii Type F ToxinJournal of Clinical Microbiology, 2002
- Mechanism of action of sodium cyanide on rat diaphragm muscleJournal of Applied Toxicology, 1999
- Efficacy of a novel metalloprotease inhibitor on botulinum neurotoxin B activityFEBS Letters, 1998
- 1.8‐Å Crystal Structure of the Catalytic Domain of Human Neutrophil Collagenase (Matrix Metalloproteinase‐8) Complexed with a Peptidomimetic Hydroxamate Primed‐Side Inhibitor with a Distinct Selectivity ProfileEuropean Journal of Biochemistry, 1997
- Three-Dimensional Models of ACE and NEP Inhibitors and Their Use in the Design of Potent Dual ACE/NEP InhibitorsJournal of the American Chemical Society, 1996
- Proteolysis of synthetic peptides by type A botulinum neurotoxinProtein Journal, 1995
- Proteolytic cleavage of synthetic fragments of vesicle‐associated membrane protein, isoform‐2 by botulinum type B neurotoxinEuropean Journal of Biochemistry, 1993